IP Library › Granted Patent US 12,128,113
Granted Patent B2
US 12,128,113 · App. 16/302,607 · Granted Oct 29, 2024

Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome

Inventors: Kerry Benenato (Sudbury, MA); Stephen Hoge (Brookline, MA); Paolo Martini (Boston, MA); Iain Mcfadyen (Arlington, MA); Vladimir Presnyak (Manchester, NH); Ding An (Waban, MA); Ellalahewage Sathyajith Kumarasinghe (Harvard, MA)
Assignee: ModernaTX, Inc.
A61K48/0066A61K9/51A61K47/14A61K47/16A61K47/22A61K47/24A61K48/0041C12N15/88A61K9/1271A61K9/5123A61K47/10A61K47/28C07K14/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,128,113
App. No.
16/302,607
Granted
Oct 29, 2024
Kind
B2
Abstract

The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

Claims (117)

1. A composition comprising:

a lipid nanoparticle and

a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a human Jagged1 (JAG1) polypeptide,

wherein the lipid nanoparticle comprises an ionizable lipid, and

wherein the ionizable lipid comprises a compound of Formula (IIa), (IIc), or (IIe):

or a salt or stereoisomer thereof, wherein

R 4 is unsubstituted C 1-3 alkyl, or —(CH 2 ) n Q, in which n is 1, 2, 3, 4 or 5 and Q is OH, —NHC(S)N(R) 2 , or —NHC(O)N(R) 2 ; and

each R is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H.

2. The composition of claim 1 , wherein n is 2.

3. The composition of claim 1 , wherein the ionizable lipid comprises the compound of the formula:

or a salt thereof.

4. The composition of claim 1 , wherein the lipid nanoparticle further comprises a phospholipid, a structural lipid, and a PEG lipid.

5. The composition of claim 4 , wherein the phospholipid is selected from the group consisting of:

1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC);

1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC);

1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC);

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC);

1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC);

1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC);

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC);

1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC);

1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC);

1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC);

1,2-dilinolenoyl-sn-glycero-3-phosphocholine;

1,2-diarachidonoyl-sn-glycero-3-phosphocholine;

1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine;

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE);

1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE);

1,2-distearoyl-sn-glycero-3-phosphoethanolamine;

1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine;

1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine;

1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine;

1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine;

1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG);

sphingomyelin; and

mixtures thereof.

6. The composition of claim 1 , wherein the mRNA further comprises a microRNA (miRNA) binding site.

7. A pharmaceutical composition comprising a lipid nanoparticle and an mRNA comprising an ORF encoding a human JAG1 polypeptide, wherein the lipid nanoparticle comprises an ionizable lipid, and wherein the ionizable lipid comprises a compound selected from the group consisting of

or salts and stereoisomers thereof, and any combination thereof.

8. The composition of claim 4 , wherein the structural lipid is selected from the group consisting of: cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

9. The composition of claim 4 , wherein the PEG lipid is selected from the group consisting of: a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

10. The composition of claim 4 , wherein the PEG lipid is (Compound 428).

11. A composition comprising:

(a) a lipid nanoparticle; and

(b) a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a human Jagged1 (JAG1) polypeptide,

wherein the lipid nanoparticle comprises

(i) the ionizable lipid of the formula

(ii) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),

(iii) cholesterol, and

(iv) a PEG lipid of the formula

12. The composition of claim 1 , wherein the ORF comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.

13. The composition of claim 12 , wherein the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil (ψ), N1-methylpseudouracil (m1ψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4′-thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combination thereof.

14. The composition of claim 12 , wherein the at least one chemically modified nucleobase is N1-methylpseudouracil (m1ψ).

15. The composition of claim 3 , wherein the lipid nanoparticle further comprises a phospholipid, a structural lipid, and a PEG lipid.

16. The composition of claim 15 , wherein the phospholipid is selected from the group consisting of:

1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC);

1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC);

1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC);

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC);

1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC);

1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC);

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC);

1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC);

1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC);

1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC);

1,2-dilinolenoyl-sn-glycero-3-phosphocholine;

1,2-diarachidonoyl-sn-glycero-3-phosphocholine;

1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine;

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE);

1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE);

1,2-distearoyl-sn-glycero-3-phosphoethanolamine;

1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine;

1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine;

1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine;

1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine;

1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG);

sphingomyelin; and

mixtures thereof.

17. The composition of claim 3 , wherein the mRNA further comprises a microRNA (miRNA) binding site.

18. The composition of claim 15 , wherein the structural lipid is selected from the group consisting of: cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

19. The composition of claim 15 , wherein the PEG lipid is selected from the group consisting of: a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

20. The composition of claim 15 , wherein the PEG lipid is

21. The composition of claim 3 , wherein the ORF comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.

22. The composition of claim 12 , wherein the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil (ψ), N1-methylpseudouracil (m1ψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4′-thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combination thereof.

23. The composition of claim 22 , wherein the at least one chemically modified nucleobase is N1-methylpseudouracil (m1ψ).

24. The composition of claim 7 , wherein the lipid nanoparticle further comprises a phospholipid, a structural lipid, and a PEG lipid.

25. The composition of claim 24 , wherein the phospholipid is selected from the group consisting of:

1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC);

1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC);

1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC);

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC);

1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC);

1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC);

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC);

1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC);

1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC);

1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC);

1,2-dilinolenoyl-sn-glycero-3-phosphocholine;

1,2-diarachidonoyl-sn-glycero-3-phosphocholine;

1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine;

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE);

1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE);

1,2-distearoyl-sn-glycero-3-phosphoethanolamine;

1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine;

1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine;

1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine;

1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine;

1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG);

sphingomyelin; and

mixtures thereof.

26. The composition of claim 7 , wherein the mRNA further comprises a microRNA (miRNA) binding site.

27. The composition of claim 24 , wherein the structural lipid is selected from the group consisting of: cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

28. The composition of claim 24 , wherein the PEG lipid is selected from the group consisting of: a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

29. The composition of claim 24 , wherein the PEG lipid is

30. The composition of claim 7 , wherein the ORF comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.

31. The composition of claim 30 , wherein the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil (ψ), N1-methylpseudouracil (m1ψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4′-thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combination thereof.

32. The composition of claim 30 , wherein the at least one chemically modified nucleobase is N1-methylpseudouracil (m1ψ).

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2019
From: BENENATO, KERRY; HOGE, STEPHEN; MARTINI, PAOLO; MCFADYEN, IAIN; PRESNYAK, VLADIMIR; AN, DING; KUMARASINGHE, ELLALAHEWAGE SATHYAJITH
To: MODERNATX, INC.
Reel/Frame 048301/0595 →